MOLNUPIRAVIR AND FAVIPIRAVIR SHOULD NOT BE USED FOR WOMEN PLANNING TO BECOME PREGNANT
The Official Dispatch No. 151/SYT-NVY on updating the “Guidance on medical bags for COVID-19 patients undergoing treatment at home” (Version 1.7) is promulgated by the Department of Health of Ho Chi Minh City on January 06, 2022.
Specifically, COVID-19 patients undergoing treatment at home must fully meet 2 clinical criteria. Firstly, having asymptomatic or mild symptoms (without respiratory distress: SpO2 ≥ 97% when breathing air, respiratory rate ≤ 20 breaths per minute). Secondly, being from 3 months to 64 years old, without underlying medical conditions, pregnancy, or obesity, having received full doses of vaccines; those who do not fully satisfy the above-mentioned conditions may be quarantined at home, provided that they have a stable underlying medical condition, don't have any abnormal symptoms, have received full doses of COVID-19 vaccines or have received the first dose of COVID-19 vaccine for 14 days and wish to be quarantined at home.
Drugs for COVID-19 treatment at home include 3 bags (A, B, C): The bag A includes common drugs such as antipyretics drugs and supplements; The bag B includes anti-inflammatories and anticoagulants; The bag C includes an antiviral drug used under the Ministry of Health's Program on the controlled use of Molnupiravir in the community for COVID-19 patients with mild symptoms.
Remarkably, Molnupiravir should not be used for women who are pregnant or plan to become pregnant or breastfeeding. Favipiravir should not be used for those who are pregnant or plan to become pregnant, breastfeeding, have severe liver or kidney failure.
